The pipeline comprises oral solids and parenteral formulations in both the potent and non-potent compounds categories, in the core therapeutic areas of metabolics, cardiovascular, oncology and immunotherapy.
CONTACT
Group Companies
GENERIC FORMULATIONS
Pipeline
Our products
Tacrolimus
Commercialized in
United States
Rosuvastatin
Commercialized in
United States & EU
Simvastatin
Commercialized in
United States
Atorvastatin
Commercialized in
United States
Pravastatin
Commercialized in
United States
Everolimus
Commercialized in
U.S. & Approved in EU
Fingolimod
Approved in
United States & EU
Pemetrexed
Tentative Approval
(United States)
Dapagliflozin
Tentative Approval
(United States)
Labetalol
Commercialized In
United States
Esomeprazole
Commercialized In
United States
Posaconazole
Commercialized in
United States
Filings
To support our filings, we commissioned our first oral solid dosage facility in Bengaluru. The facility successfully completed several regulatory audits subsequently following our various filings in the U.S. and Europe. We have built commercial infrastructure to support this initiative in the U.S.
For more information on FORMULATIONS, please send your enquiry to: contactus.formulations@biocon.com
PRESS RELEASES
CORPORATE GOVERNANCE
